Cara Therapeutics to Participate in October Medical Meetings
October 12 2016 - 4:30PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced its
participation at two upcoming medical meetings, both of which will
be held in Chicago.
At the 10th Annual Pain & Migraine
Therapeutics Summit (to be held October 19-20, 2016), Dr. Joseph
Stauffer, Cara’s Chief Medical Officer, will speak on an expert
panel and deliver a presentation on kappa opioid receptor agonists
(KORAs) as a novel approach to acute and chronic pain
management.
At ANESTHESIOLOGY® 2016 (to be held October
22-26, 2016), Dr. Stauffer will moderate a satellite symposium
discussing therapies currently used in enhanced recovery after
surgery, and review the unique pharmacological properties of CR845,
Cara’s first-in-class peripherally selective kappa opioid agonist.
Clinical trial results to date support the view that CR845 is
unlikely to be recreationally abused or lead to physical
dependence.
10th Annual Pain & Migraine
Therapeutics Summit
The expert panel details are as follows:
Title: “Pain, Policies
and Predicaments - Follow-Up Panel
Discussion”Date: Wednesday, October 19,
2016Time: 10:10 a.m.
CTLocation: Embassy Suites by Hilton Chicago
DowntownChair: Lynn Webster, M.D.,
F.A.C.P.M., F.A.S.A.M., Vice President of Scientific Affairs, PRA
Health Sciences, Past President, American Academy of Pain
MedicinePanelists:
- Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara
Therapeutics; Assistant Professor, Department of Anesthesiology
& Critical Care Medicine, Johns Hopkins University School of
Medicine
- Carl L. Roland, Pharm.D., M.S., Senior Director, Pfizer,
Inc.
- Alexander Kraus, Ph.D., Vice President of Product Development,
Technical & Government Affairs, Grunenthal USA, Inc.
Details of Dr. Stauffer’s presentation are as
follows:
Title: “Kappa Opioid
Receptor Agonists (KORAs): A Novel Approach to Managing Acute and
Chronic Pain”Date: Wednesday, October 19,
2016Time: 11:00 a.m.
CTLocation: Embassy Suites by Hilton Chicago
Downtown
For more information on the 10th Annual Pain
& Migraine Therapeutics Summit, visit:
http://www.paintherapeuticsummit.com/.
ANESTHESIOLOGY®
2016
The satellite symposium details are as
follows:
Title: “Emerging
Analgesic Options for Enhanced Recovery”Date:
Sunday, October 23, 2016Time: 7:00 –
8:00 a.m. CTLocation: Regency Ballroom BC,
Hyatt Regency ChicagoModerator: Joseph
Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics;
Assistant Professor, Department of Anesthesiology & Critical
Care Medicine, Johns Hopkins University School of
MedicineFaculty: Randal O. Dull, M.D.,
Ph.D., Professor and Vice Chair for Research, Department of
Anesthesiology; Professor, Departments of Bioengineering,
Biopharmaceutical Sciences and Pharmacology, University of Illinois
College of Medicine
For more information on ANESTHESIOLOGY® 2016, visit:
https://www.asahq.org/annualmeeting.
About CR845
CR845 is a peripherally acting kappa opioid
receptor agonist currently in development for the treatment of
acute and chronic pain and pruritus. In multiple randomized,
double-blind, placebo-controlled Phase 2 trials in patients
undergoing laparoscopic hysterectomy or bunionectomy procedures,
I.V. CR845 treatment resulted in statistically significant
reductions in both pain intensity and opioid-related side effects.
In a human abuse liability trial, I.V. CR845 demonstrated
statistically significant reductions in “drug liking,” “feeling
high,” “overall liking,” and “take drug again” scores in comparison
to I.V. pentazocine, a Schedule IV analgesic.
An oral formulation of CR845 is currently being
evaluated in a Phase 2b study in osteoarthritis patients and was
shown in a Phase 2a study to be well tolerated with twice a day
dosing for two weeks, with evidence of decreasing pain scores
during that time period.
In approximately 1,150 subjects dosed to date,
CR845 was found to be well tolerated, without incurring the
dysphoric and psychotomimetic side effects that have been reported
with centrally acting (CNS-active) kappa opioid receptor
agonists.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biotechnology company focused on developing and commercializing new
chemical entities designed to alleviate pain and pruritus by
selectively targeting peripheral kappa opioid receptors. Cara is
developing a novel and proprietary class of product candidates that
target the body's peripheral nervous system and have demonstrated
initial efficacy in patients with moderate-to-severe pain without
inducing many of the undesirable side effects typically associated
with currently available pain therapeutics.
INVESTOR CONTACT:
Jesse Baumgartner
Stern Investor Relations, Inc.
212-362-1200
jesse@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024